You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameGuanfacine
Accession NumberDB01018  (APRD00075)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA centrally acting antihypertensive agent. The drug lowers both systolic and diastolic blood pressure by activating the central nervous system alpha-2 adrenoreceptors, which results in reduced sympathetic outflow leading to reduced vascular tone. Its adverse reactions include dry mouth, sedation, and constipation. [PubChem]
Structure
Thumb
Synonyms
Estulic
Guanfacina
Guanfacinum
External Identifiers
  • SPD 503
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IntunivTablet, extended release1 mg/1OralTYA Pharmaceuticals2009-09-02Not applicableUs
IntunivTablet, extended release4 mgOralShire Pharmaceuticals Ireland Ltd2015-09-17Not applicableEu
IntunivTablet, extended release2 mgOralShire Pharmaceuticals Ireland Ltd2015-09-17Not applicableEu
IntunivTablet, extended release3 mg/1OralShire US Manufacturing Inc.2009-09-02Not applicableUs
IntunivTablet, extended release1 mgOralShire Pharmaceuticals Ireland Ltd2015-09-17Not applicableEu
IntunivTablet, extended release2 mg/1OralTYA Pharmaceuticals2009-09-02Not applicableUs
IntunivTablet, extended release4 mgOralShire Pharmaceuticals Ireland Ltd2015-09-17Not applicableEu
IntunivTablet, extended release2 mgOralShire Pharmaceuticals Ireland Ltd2015-09-17Not applicableEu
IntunivTablet, extended release4 mg/1OralShire US Manufacturing Inc.2009-09-02Not applicableUs
IntunivTablet, extended release1 mgOralShire Pharmaceuticals Ireland Ltd2015-09-17Not applicableEu
IntunivTablet, extended release1 mg/1OralShire US Manufacturing Inc.2009-09-02Not applicableUs
IntunivTablet, extended release3 mgOralShire Pharmaceuticals Ireland Ltd2015-09-17Not applicableEu
IntunivKitShire US Manufacturing Inc.2009-09-02Not applicableUs
IntunivTablet, extended release2 mgOralShire Pharmaceuticals Ireland Ltd2015-09-17Not applicableEu
IntunivTablet, extended release2 mg/1OralShire US Manufacturing Inc.2009-09-02Not applicableUs
IntunivTablet, extended release3 mgOralShire Pharmaceuticals Ireland Ltd2015-09-17Not applicableEu
Intuniv XRTablet, extended release3 mgOralShire Pharma Canada Ulc2013-08-06Not applicableCanada
Intuniv XRTablet, extended release2 mgOralShire Pharma Canada Ulc2013-08-06Not applicableCanada
Intuniv XRTablet, extended release4 mgOralShire Pharma Canada Ulc2013-08-06Not applicableCanada
Intuniv XRTablet, extended release1 mgOralShire Pharma Canada Ulc2013-08-06Not applicableCanada
TenexTablet1 mg/1OralPromius Pharma, LLC1986-10-27Not applicableUs
TenexTablet2 mg/1OralPromius Pharma, LLC1986-10-27Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GuanfacineTablet, extended release1 mg/1OralActavis Pharma, Inc.2014-12-01Not applicableUs
GuanfacineTablet2 mg/1OralPhysicians Total Care, Inc.2003-07-31Not applicableUs
GuanfacineTablet1 mg/1OralMylan Pharmaceuticals Inc.1997-01-28Not applicableUs
GuanfacineTablet1 mg/1OralREMEDYREPACK INC.2016-01-13Not applicableUs
GuanfacineTablet1 mg/1OralGolden State Medical Supply, Inc.2014-04-22Not applicableUs
GuanfacineTablet, extended release4 mg/1OralAv Kare, Inc.2015-07-07Not applicableUs
GuanfacineTablet2 mg/1OralPura Cap Laboratories, Llc2016-11-14Not applicableUs
GuanfacineTablet, extended release2 mg/1OralTeva Pharmaceuticals USA Inc2015-06-02Not applicableUs
GuanfacineTablet, extended release2 mg/1OralActavis Pharma, Inc.2014-12-01Not applicableUs
GuanfacineTablet1 mg/1OralPhysicians Total Care, Inc.1995-10-17Not applicableUs
GuanfacineTablet2 mg/1OralMylan Pharmaceuticals Inc.1997-01-28Not applicableUs
GuanfacineTablet, extended release1 mg/1OralAv Kare, Inc.2015-07-07Not applicableUs
GuanfacineTablet2 mg/1OralGolden State Medical Supply, Inc.2014-04-22Not applicableUs
GuanfacineTablet, extended release3 mg/1OralTeva Pharmaceuticals USA Inc2015-06-02Not applicableUs
GuanfacineTablet1 mg/1OralEpic Pharma, LLC2013-12-02Not applicableUs
GuanfacineTablet, extended release3 mg/1OralActavis Pharma, Inc.2014-12-01Not applicableUs
GuanfacineTablet1 mg/1OralCardinal Health1995-10-17Not applicableUs
GuanfacineTablet1 mg/1OralActavis Pharma, Inc.1995-10-17Not applicableUs
GuanfacineTablet1 mg/1OralCarilion Materials Management1995-10-17Not applicableUs
GuanfacineTablet, extended release2 mg/1OralAv Kare, Inc.2015-07-07Not applicableUs
GuanfacineTablet1 mg/1OralProficient Rx LP2013-12-02Not applicableUs
GuanfacineTablet, extended release4 mg/1OralTeva Pharmaceuticals USA Inc2015-06-02Not applicableUs
GuanfacineTablet2 mg/1OralEpic Pharma, LLC2013-12-02Not applicableUs
GuanfacineTablet, extended release4 mg/1OralActavis Pharma, Inc.2014-12-01Not applicableUs
GuanfacineTablet1 mg/1OralCardinal Health1997-01-27Not applicableUs
GuanfacineTablet1 mg/1OralPura Cap Laboratories, Llc2016-11-14Not applicableUs
GuanfacineTablet2 mg/1OralActavis Pharma, Inc.1995-10-17Not applicableUs
GuanfacineTablet, extended release1 mg/1OralTeva Pharmaceuticals USA Inc2015-06-02Not applicableUs
GuanfacineTablet, extended release3 mg/1OralAv Kare, Inc.2015-07-07Not applicableUs
Guanfacine Extended-releaseTablet, extended release4 mg/1OralSandoz Inc2015-06-03Not applicableUs
Guanfacine Extended-releaseTablet, extended release2 mg/1OralPar Pharmaceutical Inc.2015-06-02Not applicableUs
Guanfacine Extended-releaseTablet, extended release1 mg/1OralSandoz Inc2015-06-03Not applicableUs
Guanfacine Extended-releaseTablet, extended release3 mg/1OralPar Pharmaceutical Inc.2015-06-02Not applicableUs
Guanfacine Extended-releaseTablet, extended release2 mg/1OralSandoz Inc2015-06-03Not applicableUs
Guanfacine Extended-releaseTablet, extended release4 mg/1OralPar Pharmaceutical Inc.2015-06-02Not applicableUs
Guanfacine Extended-releaseTablet, extended release3 mg/1OralSandoz Inc2015-06-03Not applicableUs
Guanfacine Extended-releaseTablet, extended release1 mg/1OralPar Pharmaceutical Inc.2015-06-02Not applicableUs
Guanfacine HydrochlorideTablet2 mg/1OralAmneal Pharmaceuticals of New York, LLC1998-11-25Not applicableUs
Guanfacine HydrochlorideTablet2 mg/1OralAv Kare, Inc.1998-11-25Not applicableUs
Guanfacine HydrochlorideTablet, film coated, extended release1 mg/1OralMylan Pharmaceuticals Inc.2015-06-02Not applicableUs
Guanfacine HydrochlorideTablet1 mg/1OralMajor Pharmaceuticals1998-11-25Not applicableUs
Guanfacine HydrochlorideTablet1 mg/1OralAmerican Health Packaging2014-05-30Not applicableUs
Guanfacine HydrochlorideTablet1 mg/1OralAtlantic Biologicals Corps1998-11-25Not applicableUs
Guanfacine HydrochlorideTablet, film coated, extended release2 mg/1OralMylan Pharmaceuticals Inc.2015-06-02Not applicableUs
Guanfacine HydrochlorideTablet2 mg/1OralMajor Pharmaceuticals1998-11-25Not applicableUs
Guanfacine HydrochlorideTablet, film coated, extended release3 mg/1OralMylan Pharmaceuticals Inc.2015-06-02Not applicableUs
Guanfacine HydrochlorideTablet1 mg/1OralTYA Pharmaceuticals1998-11-25Not applicableUs
Guanfacine HydrochlorideTablet1 mg/1OralAv Kare, Inc.1998-11-25Not applicableUs
Guanfacine HydrochlorideTablet, film coated, extended release4 mg/1OralMylan Pharmaceuticals Inc.2015-06-02Not applicableUs
Guanfacine HydrochlorideTablet1 mg/1OralAmneal Pharmaceuticals of New York, LLC1998-11-25Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EstulicEgis
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Guanfacine Hydrochloride
Thumb
  • InChI Key: DGFYECXYGUIODH-UHFFFAOYSA-N
  • Monoisotopic Mass: 280.988945078
  • Average Mass: 282.554
DBSALT000509
Categories
UNII30OMY4G3MK
CAS number29110-47-2
WeightAverage: 246.093
Monoisotopic: 245.012267339
Chemical FormulaC9H9Cl2N3O
InChI KeyINJOMKTZOLKMBF-UHFFFAOYSA-N
InChI
InChI=1S/C9H9Cl2N3O/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13/h1-3H,4H2,(H4,12,13,14,15)
IUPAC Name
N-carbamimidoyl-2-(2,6-dichlorophenyl)acetamide
SMILES
NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl
Pharmacology
IndicationFor use alone or in combination with other classes of antihypertensive agents in the management of hypertension. Has also been used for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric patients.
Structured Indications
PharmacodynamicsGuanfacine is a phenylacetyl-guanidine derivative hypotensive and a centrally-acting, alpha(2)-adrenergic receptor agonist used alone or in combination with other drugs for the treatment of hypertension.
Mechanism of actionGuanfacine selectively stimulates central alpha(2)-adrenergic receptors, resulting in inhibition of sympathetic vasomotor centers, which contributes predominantly to the hypotensive effects of the drug. Central effects of guanfacine lead to reduced peripheral sympathetic nerve impulses from the vasomotor center to the heart and blood vessels. This results in a decrease in peripheral vascular resistance and a reduction in heart rate. The stimulation of peripheral alpha(2)-adrenergic receptors may also contribute to hypotensive effects.
TargetKindPharmacological actionActionsOrganismUniProt ID
Alpha-2A adrenergic receptorProteinyes
agonist
HumanP08913 details
Alpha-2B adrenergic receptorProteinunknown
binder
HumanP18089 details
Related Articles
AbsorptionRapid and complete, with an oral bioavailability of approximately 80%.
Volume of distribution
  • 6.3 L/kg
Protein bindingApproximately 70% bound to plasma proteins, independent of drug concentration.
Metabolism

Hepatic

SubstrateEnzymesProduct
Guanfacine
3-hydroxyguanfacine glucuronideDetails
Route of eliminationIn individuals with normal renal function, guanfacine and its metabolites are excreted primarily in the urine.
Half life17 hours (range 10-30 hours)
ClearanceNot Available
ToxicitySymptoms of overdose include drowsiness, lethargy, bradycardia and hypotension. LD50=165mg/kg (orally in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Guanfacine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Guanfacine.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Guanfacine.Experimental
AbirateroneThe metabolism of Guanfacine can be decreased when combined with Abiraterone.Approved
AcebutololGuanfacine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Guanfacine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Guanfacine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Acetazolamide.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Guanfacine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Guanfacine.Approved, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Guanfacine.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Guanfacine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Guanfacine.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Guanfacine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Guanfacine is combined with Aliskiren.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Guanfacine.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Guanfacine.Approved, Illicit, Investigational
AlprenololGuanfacine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmbrisentanGuanfacine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineGuanfacine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Guanfacine.Approved
AmineptineAmineptine may decrease the antihypertensive activities of Guanfacine.Illicit, Withdrawn
AmiodaroneThe serum concentration of Guanfacine can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Guanfacine.Approved, Investigational
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Guanfacine.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Guanfacine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Guanfacine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Guanfacine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Guanfacine.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Guanfacine is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Guanfacine is combined with Amyl Nitrite.Approved
Aop200704Guanfacine may increase the atrioventricular blocking (AV block) activities of Aop200704.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Guanfacine.Approved
AprepitantThe serum concentration of Guanfacine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Guanfacine.Approved, Investigational
ArmodafinilThe metabolism of Guanfacine can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololGuanfacine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Arsenic trioxide.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Guanfacine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Guanfacine.Approved
AtazanavirThe serum concentration of Guanfacine can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololGuanfacine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AtomoxetineThe metabolism of Guanfacine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Guanfacine.Vet Approved
AzelastineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Guanfacine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Guanfacine is combined with Azilsartan medoxomil.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Guanfacine.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Guanfacine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Guanfacine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Barnidipine.Approved
BefunololGuanfacine may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Guanfacine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Guanfacine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Guanfacine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Guanfacine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Guanfacine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Guanfacine.Approved
Benzylpenicilloyl PolylysineGuanfacine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilGuanfacine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeractantGuanfacine may increase the bradycardic activities of Beractant.Approved
BetaxololGuanfacine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BethanidineBethanidine may increase the hypotensive activities of Guanfacine.Approved
BevantololGuanfacine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BexaroteneThe serum concentration of Guanfacine can be decreased when it is combined with Bexarotene.Approved, Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Guanfacine.Approved, Investigational
BisoprololGuanfacine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BoceprevirThe serum concentration of Guanfacine can be increased when it is combined with Boceprevir.Approved
BopindololGuanfacine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BortezomibThe metabolism of Guanfacine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Guanfacine can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Guanfacine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Guanfacine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Guanfacine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Guanfacine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Guanfacine.Approved, Illicit
BromocriptineBromocriptine may increase the hypertensive activities of Guanfacine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Guanfacine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Guanfacine.Approved, Withdrawn
BucindololGuanfacine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BufuralolGuanfacine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Guanfacine.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Guanfacine.Approved, Investigational
BupranololGuanfacine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BuprenorphineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Guanfacine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Guanfacine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Guanfacine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Guanfacine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Guanfacine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Guanfacine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Guanfacine.Approved, Illicit, Vet Approved
CabergolineCabergoline may increase the hypertensive activities of Guanfacine.Approved
CalfactantGuanfacine may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Guanfacine.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Guanfacine.Experimental
CapecitabineThe metabolism of Guanfacine can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Guanfacine is combined with Captopril.Approved
CarbamazepineThe serum concentration of Guanfacine can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Carbetocin.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Guanfacine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Guanfacine.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Guanfacine.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Guanfacine.Withdrawn
CarteololGuanfacine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolGuanfacine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CeliprololGuanfacine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CeritinibGuanfacine may increase the bradycardic activities of Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Guanfacine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Guanfacine.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Guanfacine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Guanfacine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Guanfacine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Guanfacine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Guanfacine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Guanfacine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Guanfacine.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Guanfacine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Guanfacine.Approved
CholecalciferolThe metabolism of Guanfacine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThe risk or severity of adverse effects can be increased when Guanfacine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Cilnidipine.Approved
CimetidineThe metabolism of Guanfacine can be decreased when combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Guanfacine.Approved, Vet Approved
CitalopramThe metabolism of Guanfacine can be decreased when combined with Citalopram.Approved
ClarithromycinThe serum concentration of Guanfacine can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Guanfacine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Guanfacine.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Guanfacine.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Clofarabine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Guanfacine.Investigational
ClomipramineClomipramine may decrease the antihypertensive activities of Guanfacine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Guanfacine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Guanfacine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Guanfacine.Approved, Illicit
ClotrimazoleThe metabolism of Guanfacine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Guanfacine.Approved
CobicistatThe serum concentration of Guanfacine can be increased when it is combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Guanfacine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Guanfacine.Approved, Illicit
ConivaptanThe serum concentration of Guanfacine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Guanfacine can be decreased when combined with Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Guanfacine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Guanfacine.Approved
CyclosporineThe metabolism of Guanfacine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Guanfacine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Guanfacine.Approved
DabrafenibThe serum concentration of Guanfacine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Guanfacine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dapoxetine.Investigational
DarunavirThe serum concentration of Guanfacine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Guanfacine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinGuanfacine may increase the hypotensive activities of Debrisoquin.Approved
DeferasiroxThe serum concentration of Guanfacine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Guanfacine can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Guanfacine.Investigational
DeserpidineGuanfacine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Guanfacine.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Guanfacine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Guanfacine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Guanfacine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Guanfacine.Vet Approved
DexamethasoneThe serum concentration of Guanfacine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Guanfacine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Guanfacine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Guanfacine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Guanfacine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Guanfacine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Guanfacine.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Guanfacine.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Diclofenamide.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Difenoxin.Approved, Illicit
DigoxinDigoxin may increase the bradycardic activities of Guanfacine.Approved
DihydralazineGuanfacine may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Guanfacine.Approved, Illicit
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Guanfacine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Guanfacine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Guanfacine.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Guanfacine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Guanfacine.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dinutuximab.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Guanfacine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Guanfacine.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Guanfacine.Approved
DonepezilDonepezil may increase the bradycardic activities of Guanfacine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Guanfacine.Vet Approved
DorzolamideDorzolamide may increase the hypotensive activities of Guanfacine.Approved
DosulepinDosulepin may decrease the antihypertensive activities of Guanfacine.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Guanfacine.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Guanfacine.Approved
DoxycyclineThe metabolism of Guanfacine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Guanfacine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Illicit
DronedaroneThe metabolism of Guanfacine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Guanfacine.Experimental, Illicit
DuloxetineGuanfacine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Guanfacine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Guanfacine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Guanfacine.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Guanfacine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineGuanfacine may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Guanfacine.Approved, Vet Approved
EnalaprilatGuanfacine may increase the hypotensive activities of Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Guanfacine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Guanfacine.Approved, Investigational
EnzalutamideThe serum concentration of Guanfacine can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Guanfacine.Approved
EpoprostenolGuanfacine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Guanfacine.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Guanfacine.Approved
ErgonovineErgonovine may increase the hypertensive activities of Guanfacine.Approved
ErgotamineErgotamine may increase the hypertensive activities of Guanfacine.Approved
ErythromycinThe metabolism of Guanfacine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Guanfacine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Guanfacine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Guanfacine.Investigational
EsmololGuanfacine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EsomeprazoleThe metabolism of Guanfacine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Guanfacine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Guanfacine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Guanfacine.Approved
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Guanfacine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Guanfacine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Guanfacine.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Guanfacine.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Guanfacine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Guanfacine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Guanfacine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Guanfacine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Guanfacine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Guanfacine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Guanfacine.Illicit, Vet Approved
EtravirineThe serum concentration of Guanfacine can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Guanfacine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Guanfacine.Approved, Illicit, Withdrawn
FenoldopamFenoldopam may increase the hypotensive activities of Guanfacine.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Guanfacine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Guanfacine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Guanfacine is combined with Fimasartan.Approved
FingolimodGuanfacine may increase the bradycardic activities of Fingolimod.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Flibanserin.Approved
FloxuridineThe metabolism of Guanfacine can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Guanfacine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Guanfacine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Guanfacine.Approved, Illicit
FluorouracilThe metabolism of Guanfacine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Guanfacine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Guanfacine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Guanfacine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Guanfacine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Guanfacine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Guanfacine.Approved
FluvastatinThe metabolism of Guanfacine can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Guanfacine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Guanfacine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Guanfacine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Guanfacine.Approved
FosphenytoinThe serum concentration of Guanfacine can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Guanfacine.Approved, Illicit
FurazolidoneFurazolidone may increase the hypotensive activities of Guanfacine.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Guanfacine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Guanfacine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Guanfacine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Guanfacine is combined with gabapentin enacarbil.Approved
GalantamineGalantamine may increase the bradycardic activities of Guanfacine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Guanfacine.Approved, Illicit
GemfibrozilThe metabolism of Guanfacine can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Guanfacine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Guanfacine.Approved, Illicit
GuanabenzGuanabenz may increase the hypotensive activities of Guanfacine.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Guanfacine.Approved
GuanethidineGuanfacine may increase the hypotensive activities of Guanethidine.Approved
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Guanfacine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Guanfacine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Guanfacine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Guanfacine.Approved, Illicit
HexamethoniumGuanfacine may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Guanfacine.Approved
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Guanfacine.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Guanfacine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Guanfacine.Approved, Vet Approved
HydrocodoneGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Guanfacine.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Guanfacine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved
IdelalisibThe serum concentration of Guanfacine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Iloperidone.Approved
IloprostIloprost may increase the hypotensive activities of Guanfacine.Approved, Investigational
ImatinibThe metabolism of Guanfacine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Guanfacine is combined with Imidapril.Investigational
ImipramineImipramine may decrease the antihypertensive activities of Guanfacine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Guanfacine.Approved
IndenololGuanfacine may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Guanfacine can be increased when it is combined with Indinavir.Approved
IndoraminGuanfacine may increase the hypotensive activities of Indoramin.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Guanfacine.Approved
IproclozideIproclozide may increase the hypotensive activities of Guanfacine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Guanfacine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Guanfacine is combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Guanfacine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Guanfacine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Guanfacine.Approved, Vet Approved
IsoniazidThe metabolism of Guanfacine can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Guanfacine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Guanfacine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Guanfacine.Approved
ItraconazoleThe serum concentration of Guanfacine can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineGuanfacine may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Guanfacine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Guanfacine.Approved, Vet Approved
KetanserinGuanfacine may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Guanfacine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Guanfacine.Approved
KetoconazoleThe serum concentration of Guanfacine can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolGuanfacine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LacidipineGuanfacine may increase the hypotensive activities of Lacidipine.Approved
LacosamideGuanfacine may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Guanfacine.Approved, Investigational
LanreotideGuanfacine may increase the bradycardic activities of Lanreotide.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Guanfacine.Approved, Investigational
LeflunomideThe metabolism of Guanfacine can be decreased when combined with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Guanfacine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Guanfacine is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Guanfacine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Guanfacine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Levocetirizine.Approved
LevodopaGuanfacine may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Guanfacine.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Guanfacine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Guanfacine.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Guanfacine is combined with Levosimendan.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Guanfacine.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Guanfacine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Guanfacine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Guanfacine.Illicit
LofexidineGuanfacine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirThe serum concentration of Guanfacine can be increased when it is combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Guanfacine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Guanfacine.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Guanfacine.Approved
LovastatinThe metabolism of Guanfacine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Guanfacine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Guanfacine.Investigational
LucinactantGuanfacine may increase the bradycardic activities of Lucinactant.Approved
LuliconazoleThe serum concentration of Guanfacine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Guanfacine can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Guanfacine.Approved
MacitentanGuanfacine may increase the hypotensive activities of Macitentan.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Vet Approved
ManidipineGuanfacine may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Guanfacine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Guanfacine.Approved
MebanazineMebanazine may increase the hypotensive activities of Guanfacine.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Guanfacine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Guanfacine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Guanfacine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Guanfacine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Guanfacine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Guanfacine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Guanfacine.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Guanfacine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Guanfacine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Guanfacine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Guanfacine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Guanfacine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Guanfacine.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Guanfacine.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Guanfacine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Guanfacine.Approved
MethotrimeprazineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Guanfacine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Guanfacine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Guanfacine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Guanfacine.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Guanfacine.Approved
MetipranololThe risk or severity of adverse effects can be increased when Guanfacine is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Guanfacine.Approved
MetoprololGuanfacine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MetyrosineGuanfacine may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Mianserin.Approved
MibefradilGuanfacine may increase the hypotensive activities of Mibefradil.Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Guanfacine.Approved, Illicit
MifepristoneThe serum concentration of Guanfacine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the tachycardic activities of Guanfacine.Approved
MinaprineMinaprine may increase the hypotensive activities of Guanfacine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Guanfacine.Approved
MirtazapineMirtazapine may decrease the antihypertensive activities of Guanfacine.Approved
MitotaneThe serum concentration of Guanfacine can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Guanfacine can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Guanfacine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Guanfacine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Guanfacine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Guanfacine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Guanfacine.Approved, Investigational
MoxonidineGuanfacine may increase the hypotensive activities of Moxonidine.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Investigational
NadololGuanfacine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NafcillinThe serum concentration of Guanfacine can be decreased when it is combined with Nafcillin.Approved
NaftopidilGuanfacine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Guanfacine.Approved
NebivololThe risk or severity of adverse effects can be increased when Guanfacine is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Guanfacine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Guanfacine can be increased when it is combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Guanfacine can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Guanfacine can be decreased when it is combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Guanfacine.Withdrawn
NicardipineThe metabolism of Guanfacine can be decreased when combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Guanfacine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Nifedipine.Approved
NiguldipineGuanfacine may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Guanfacine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineGuanfacine may increase the hypotensive activities of Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Guanfacine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Guanfacine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Guanfacine.Approved
NitrendipineGuanfacine may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Guanfacine.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Guanfacine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Guanfacine.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Guanfacine.Approved, Illicit
NortriptylineNortriptyline may decrease the antihypertensive activities of Guanfacine.Approved
ObinutuzumabGuanfacine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Guanfacine.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Guanfacine.Approved, Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Guanfacine.Approved, Investigational
OlaparibThe metabolism of Guanfacine can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Guanfacine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Guanfacine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Guanfacine.Investigational
OmeprazoleThe metabolism of Guanfacine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Guanfacine.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Guanfacine.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Guanfacine.Approved, Illicit
OrphenadrineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Guanfacine.Investigational
OsimertinibThe serum concentration of Guanfacine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Guanfacine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Oxetacaine.Investigational
OxprenololGuanfacine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Guanfacine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Guanfacine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Guanfacine.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Guanfacine is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Guanfacine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Guanfacine.Approved
PantoprazoleThe metabolism of Guanfacine can be decreased when combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Papaverine.Approved
ParaldehydeGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylinePargyline may increase the hypotensive activities of Guanfacine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Paroxetine.Approved, Investigational
PasireotideGuanfacine may increase the bradycardic activities of Pasireotide.Approved
PenbutololGuanfacine may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Guanfacine.Approved, Vet Approved
PentobarbitalThe serum concentration of Guanfacine can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PentoliniumGuanfacine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Guanfacine.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved
PerazineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Perazine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Guanfacine.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Guanfacine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Guanfacine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Guanfacine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Guanfacine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Guanfacine.Withdrawn
PhenobarbitalThe serum concentration of Guanfacine can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Guanfacine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Guanfacine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Guanfacine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Guanfacine.Approved
PhenytoinThe serum concentration of Guanfacine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Guanfacine.Approved
PinacidilGuanfacine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololGuanfacine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Guanfacine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Piritramide.Investigational
PirlindolePirlindole may increase the hypotensive activities of Guanfacine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Guanfacine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Guanfacine is combined with Pizotifen.Approved
PolythiazideGuanfacine may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Pomalidomide.Approved
Poractant alfaGuanfacine may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe serum concentration of Guanfacine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololGuanfacine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PramipexoleGuanfacine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Guanfacine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Guanfacine.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Guanfacine.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Guanfacine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Guanfacine.Approved
PrimidoneThe serum concentration of Guanfacine can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Guanfacine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Guanfacine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Guanfacine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Promethazine.Approved
PropafenoneGuanfacine may increase the bradycardic activities of Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Guanfacine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Guanfacine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Guanfacine.Approved
PropranololGuanfacine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Guanfacine.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Guanfacine.Investigational
PyrimethamineThe metabolism of Guanfacine can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Guanfacine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Guanfacine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Guanfacine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Guanfacine.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Guanfacine.Approved
RanolazineThe metabolism of Guanfacine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Guanfacine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Guanfacine.Approved
RemikirenRemikiren may increase the hypotensive activities of Guanfacine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Guanfacine.Approved, Withdrawn
RescinnamineGuanfacine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Guanfacine.Approved
RifabutinThe serum concentration of Guanfacine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Guanfacine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Guanfacine can be decreased when it is combined with Rifapentine.Approved
RilmenidineGuanfacine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Guanfacine is combined with Riociguat.Approved
RisperidoneGuanfacine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Guanfacine can be increased when it is combined with Ritonavir.Approved, Investigational
RituximabGuanfacine may increase the hypotensive activities of Rituximab.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Guanfacine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Guanfacine.Vet Approved
RopiniroleGuanfacine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Guanfacine.Approved
RotigotineGuanfacine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Guanfacine.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Guanfacine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Guanfacine.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Guanfacine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Guanfacine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Guanfacine is combined with Sage 547.Investigational
SaprisartanGuanfacine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Guanfacine can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Guanfacine.Approved
SecobarbitalThe metabolism of Guanfacine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Guanfacine.Approved, Investigational, Vet Approved
SelexipagGuanfacine may increase the hypotensive activities of Selexipag.Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Guanfacine.Approved, Withdrawn
SertralineThe metabolism of Guanfacine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Guanfacine.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Guanfacine.Approved, Investigational
SilodosinSilodosin may decrease the vasoconstricting activities of Guanfacine.Approved
SiltuximabThe serum concentration of Guanfacine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Guanfacine can be increased when it is combined with Simeprevir.Approved
SitaxentanGuanfacine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Guanfacine is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved
SorafenibThe metabolism of Guanfacine can be decreased when combined with Sorafenib.Approved, Investigational
SotalolGuanfacine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
SpiraprilGuanfacine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Guanfacine.Approved
St. John's WortThe serum concentration of Guanfacine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Guanfacine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Guanfacine is combined with Streptokinase.Approved
SufentanilSufentanil may increase the bradycardic activities of Guanfacine.Approved, Investigational
SulfadiazineThe metabolism of Guanfacine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Guanfacine can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Guanfacine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Guanfacine.Approved
SuvorexantGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TadalafilTadalafil may increase the antihypertensive activities of Guanfacine.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tasimelteon.Approved
TelaprevirThe serum concentration of Guanfacine can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Guanfacine can be increased when it is combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Guanfacine.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Guanfacine.Approved
TemocaprilGuanfacine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Terazosin.Approved
TerlipressinGuanfacine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Guanfacine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Guanfacine.Investigational
ThalidomideGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Guanfacine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Guanfacine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Guanfacine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Guanfacine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Guanfacine.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Guanfacine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tiapride.Investigational
TiboloneGuanfacine may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe metabolism of Guanfacine can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Guanfacine can be decreased when combined with Ticlopidine.Approved
TicrynafenGuanfacine may increase the hypotensive activities of Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Guanfacine.Vet Approved
TimololGuanfacine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Guanfacine.Approved
TocilizumabThe serum concentration of Guanfacine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Guanfacine.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Guanfacine.Approved, Vet Approved
TolbutamideThe metabolism of Guanfacine can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Guanfacine.Approved, Withdrawn
ToloxatoneToloxatone may increase the hypotensive activities of Guanfacine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Guanfacine.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Guanfacine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Guanfacine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Guanfacine.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Guanfacine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Guanfacine.Approved
TravoprostTravoprost may increase the hypotensive activities of Guanfacine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Guanfacine.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Guanfacine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Guanfacine.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Guanfacine.Approved
TrichlormethiazideGuanfacine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Guanfacine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Guanfacine.Approved, Vet Approved
TrimazosinGuanfacine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanGuanfacine may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimThe metabolism of Guanfacine can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may decrease the antihypertensive activities of Guanfacine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Guanfacine.Approved
Uc1010The risk or severity of adverse effects can be increased when Guanfacine is combined with Uc1010.Investigational
UdenafilUdenafil may increase the antihypertensive activities of Guanfacine.Approved, Investigational
UnoprostoneGuanfacine may increase the hypotensive activities of Unoprostone.Approved
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Guanfacine.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Guanfacine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Guanfacine.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Guanfacine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Guanfacine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Vigabatrin.Approved
VinpocetineGuanfacine may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe serum concentration of Guanfacine can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Guanfacine.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Guanfacine.Vet Approved
XylometazolineGuanfacine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Guanfacine.Approved, Vet Approved
ZafirlukastThe metabolism of Guanfacine can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Guanfacine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Guanfacine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Guanfacine.Vet Approved
ZolpidemGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Guanfacine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Guanfacine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Guanfacine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Guanfacine.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

U.S. Patent 3,632,645.

General ReferencesNot Available
External Links
ATC CodesC02AC02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9313
Blood Brain Barrier+0.9567
Caco-2 permeable-0.5101
P-glycoprotein substrateNon-substrate0.6778
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.9833
Renal organic cation transporterNon-inhibitor0.6443
CYP450 2C9 substrateNon-substrate0.7572
CYP450 2D6 substrateNon-substrate0.7948
CYP450 3A4 substrateNon-substrate0.6475
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.8893
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.7376
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6619
Ames testNon AMES toxic0.7223
CarcinogenicityNon-carcinogens0.8107
BiodegradationNot ready biodegradable0.9843
Rat acute toxicity2.7408 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9677
hERG inhibition (predictor II)Non-inhibitor0.9285
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Shire development inc
  • Amneal pharmaceutical
  • Mikah pharma llc
  • Mylan pharmaceuticals inc
  • Watson laboratories inc
  • Promius pharma llc
Packagers
Dosage forms
FormRouteStrength
TabletOral1 mg/1
TabletOral2 mg/1
Tablet, extended releaseOral1 mg/1
Tablet, extended releaseOral2 mg/1
Tablet, extended releaseOral3 mg/1
Tablet, extended releaseOral4 mg/1
Tablet, film coated, extended releaseOral1 mg/1
Tablet, film coated, extended releaseOral2 mg/1
Tablet, film coated, extended releaseOral3 mg/1
Tablet, film coated, extended releaseOral4 mg/1
Kit
Tablet, extended releaseOral1 mg
Tablet, extended releaseOral2 mg
Tablet, extended releaseOral3 mg
Tablet, extended releaseOral4 mg
Prices
Unit descriptionCostUnit
Intuniv 1 mg 24 Hour tablet5.72USD tablet
Intuniv 2 mg 24 Hour tablet5.72USD tablet
Intuniv 3 mg 24 Hour tablet5.72USD tablet
Intuniv 4 mg 24 Hour tablet5.72USD tablet
Intuniv er 1 mg tablet5.5USD tablet
Intuniv er 2 mg tablet5.5USD tablet
Intuniv er 3 mg tablet5.5USD tablet
Intuniv er 4 mg tablet5.5USD tablet
Tenex 2 mg tablet4.3USD tablet
Tenex 1 mg tablet2.9USD tablet
Guanfacine HCl 2 mg tablet1.22USD tablet
Guanfacine 2 mg tablet1.18USD tablet
Guanfacine HCl 1 mg tablet0.91USD tablet
Guanfacine 1 mg tablet0.87USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5854290 Yes1996-03-212016-03-21Us
US6287599 Yes2001-06-202021-06-20Us
US6811794 Yes2003-01-042023-01-04Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point213-216U.S. Patent 3,632,645.
water solubility1892 mg/LNot Available
logP1.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.139 mg/mLALOGPS
logP2.28ALOGPS
logP1.74ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)12.94ChemAxon
pKa (Strongest Basic)6.65ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area78.97 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity69.63 m3·mol-1ChemAxon
Polarizability21.75 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylacetamides. These are amide derivatives of phenylacetic acids.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylacetamides
Direct ParentPhenylacetamides
Alternative Parents
Substituents
  • Phenylacetamide
  • 1,3-dichlorobenzene
  • Halobenzene
  • Chlorobenzene
  • Aryl halide
  • Aryl chloride
  • Guanidine
  • Carboxamide group
  • Carboximidamide
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Imine
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Avery RA, Franowicz JS, Studholme C, van Dyck CH, Arnsten AF: The alpha-2A-adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task. Neuropsychopharmacology. 2000 Sep;23(3):240-9. [PubMed:10942848 ]
  2. Sagvolden T: The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD). Behav Brain Funct. 2006 Dec 15;2:41. [PubMed:17173664 ]
  3. Yuan R, Wu Z, Kostenyuk IA, Burns JK: G-protein-coupled alpha2A-adrenoreceptor agonists differentially alter citrus leaf and fruit abscission by affecting expression of ACC synthase and ACC oxidase. J Exp Bot. 2005 Jul;56(417):1867-75. Epub 2005 May 31. [PubMed:15928018 ]
  4. Birnbaum SG, Podell DM, Arnsten AF: Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403. [PubMed:11164065 ]
  5. Millan MJ: Evidence that an alpha 2A-adrenoceptor subtype mediates antinociception in mice. Eur J Pharmacol. 1992 May 14;215(2-3):355-6. [PubMed:1356794 ]
  6. Stahl SM: Mechanism of action of alpha 2A-adrenergic agonists in attention-deficit/hyperactivity disorder with or without oppositional symptoms. J Clin Psychiatry. 2010 Mar;71(3):223-4. doi: 10.4088/JCP.09bs05899pur. [PubMed:20331927 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Uhlen S, Wikberg JE: Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol. 1991 Sep 17;202(2):235-43. [PubMed:1666366 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Clement B, Demesmaeker M: Microsomal catalyzed N-hydroxylation of guanfacine and reduction of N-hydroxyguanfacine. Arch Pharm (Weinheim). 1997 Oct;330(9-10):303-6. [PubMed:9396389 ]
  2. Guillouzo A, Le Bigot JF, Guguen-Guillouzo C, Kiechel JR: Presence of phase I and phase II drug metabolizing enzymes in cultured human foetal hepatocytes. Biochem Pharmacol. 1982 Jul 15;31(14):2427-30. [PubMed:6751332 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Clement B, Demesmaeker M: Microsomal catalyzed N-hydroxylation of guanfacine and reduction of N-hydroxyguanfacine. Arch Pharm (Weinheim). 1997 Oct;330(9-10):303-6. [PubMed:9396389 ]
  2. Guillouzo A, Le Bigot JF, Guguen-Guillouzo C, Kiechel JR: Presence of phase I and phase II drug metabolizing enzymes in cultured human foetal hepatocytes. Biochem Pharmacol. 1982 Jul 15;31(14):2427-30. [PubMed:6751332 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Clement B, Demesmaeker M: Microsomal catalyzed N-hydroxylation of guanfacine and reduction of N-hydroxyguanfacine. Arch Pharm (Weinheim). 1997 Oct;330(9-10):303-6. [PubMed:9396389 ]
  2. Guillouzo A, Le Bigot JF, Guguen-Guillouzo C, Kiechel JR: Presence of phase I and phase II drug metabolizing enzymes in cultured human foetal hepatocytes. Biochem Pharmacol. 1982 Jul 15;31(14):2427-30. [PubMed:6751332 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 03:58